### Harvoni Tablet
**PRODUCT DESCRIPTION:**
Harvoni is a fixed-dose combination medication that combines Ledipasvir and Sofosbuvir. It is used for the treatment of chronic hepatitis C virus (HCV) infection.
**ACTIVE INGREDIENTS:**
– **Ledipasvir (90 mg)**: An NS5A inhibitor that interferes with the replication of the hepatitis C virus by affecting viral replication and assembly.
– **Sofosbuvir (400 mg)**: An NS5B polymerase inhibitor that inhibits the viral RNA polymerase, thereby preventing the virus from replicating.
**INDICATIONS:**
Harvoni is indicated for:
– The treatment of chronic hepatitis C virus (HCV) in adults and children aged 12 years and older (weighing at least 35 kg).
– Effective against various HCV genotypes, particularly genotypes 1, 4, 5, and 6.
**DOSAGE AND ADMINISTRATION:**
– **Dosage**: The recommended dosage is one tablet taken orally once daily, with or without food.
– **Duration of Treatment**: The treatment course typically lasts from 8 to 24 weeks, depending on patient-specific factors such as:
– HCV genotype
– Previous treatment history
– Presence of liver cirrhosis
**SIDE EFFECTS:**
Common side effects of Harvoni may include:
– Fatigue
– Headache
– Nausea
– Insomnia
– Diarrhea
Serious side effects are rare but can include:
– Liver complications
– Severe allergic reactions
**CONTRAINDICATIONS:**
– Harvoni is contraindicated in patients with a known hypersensitivity to Ledipasvir, Sofosbuvir, or any component of the formulation.
– It is not suitable for individuals with decompensated liver disease (Child-Pugh Class B or C).
**IMPORTANT NOTES:**
– **Drug Interactions**: Harvoni can interact with other medications, particularly those affecting liver enzymes. Patients must inform their healthcare provider about all medications, including over-the-counter drugs and herbal supplements.
– **Monitoring**: Regular monitoring of liver function and hematological parameters may be necessary during therapy.
– **Adherence**: It is vital to adhere to the prescribed regimen to maximize the likelihood of a successful treatment outcome.
### Summary:
Harvoni combines Ledipasvir and Sofosbuvir to provide a potent treatment option for chronic hepatitis C virus infection. Patients should stick closely to their treatment plans and remain in regular contact with their healthcare provider to address any concerns or side effects that may arise. As with any medication, it is essential to seek personalized medical advice from healthcare professionals
Reviews
There are no reviews yet.